Siemens exec to lead Curetis commercialization
This article was originally published in Clinica
Molecular diagnostics firm Curetis has appointed Achim Plum to the newly-created role of chief commercial officer. Dr Plum’s in vitro diagnostics experience includes eight years at Epigenomics, after which he joined Siemens where he was focused on assessing and developing novel approaches to the IVD market. At Curetis, Dr Plum will oversee all commercial activities, including international sales, business development, marketing and medical affairs. The German firm, based in Holzgerlingen, has CE marked its Unyvero multiplexing platform and is marketing it in Europe, the Middle East and other countries outside the EU. The technology is currently being trialled in the US with the aim of getting FDA approval.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.